Логин: Пароль: ?
 
Продукты питания Ткань, одежда, обувь, постельное белье, текстиль Строительные материалы Бумага, пластик, промтовары Биотопливо Продукция для сельского хозяйства, зоотовары Косметика, средства гигиены Медицинские товары и препараты, лекарства Иное

 

Наши партнеры:

 

Новости/Аналитика

Cannabinoids and coronavirus

25.06.2020

Cannabidiol is a reasonable candidate to study in preclinical models of coronavirus. We are very far from the level of evidence needed to consider the use of cannabinoids as pharmacotherapy for viral diseases, but the continued high interest in cannabinoids as drugs provides an important opportunity for clinicians. 

Our colleagues from the journal Cannabis and Cannabinoid Research provided an opportunity to get acquainted with the studies conducted related to the analysis of verified reliable data that testify to the therapeutic properties of cannabinoids. Having partially edited the material, but without changing its essence, we provide our esteemed readers with information that will be useful for understanding what is happening in the market for medical products made on the basis of the therapeutic properties of hemp and the possibilities of hemp raw materials used during treatment, including heavy ones / chronic diseases.

In 1985, the US Food and Drug Administration (FDA) approved two drugs based on synthetic tetrahydrocannabinol (THC), Dronabinol and Nabilon, for use in the country. In 1992, Dronabinol was allowed to be used to stimulate appetite in case of exhaustion of the patient’s body, for example, due to AIDS. Cannabidiol was approved by the FDA in 2018 for the treatment of two forms of childhood epilepsy - Dravet syndrome and Lennox-Gastaut syndrome. 

There is a sufficient amount of evidence of the effectiveness of the use of cannabinoids for the relief of chronic pain, including neuropathic pain and muscle spasticity caused by multiple sclerosis. It is concluded that there is “convincing or substantial evidence” that hemp is effective in treating chronic pain in adults based on an assessment of the patients themselves. In addition, the literature on chronic pain has corroborating research results of good quality with no significant opposite results.

Cannabinoids and viral diseases

Limited data indicate the possible role of cannabinoids as therapeutic agents used to treat viral diseases. Apparently, cannabinoids can be part of a treatment regimen with non-steroidal anti-inflammatory drugs and other substances that target immune pathways that can suppress the cytokine storm. Cannabidiol (CBD) has several characteristics that make it an attractive tool for studying antiviral activity. Unlike THC, CBD is not an intoxicant and does not have the potential for abuse. In addition, CBD can induce apoptosis (a regulated process of programmed cell death) in mammalian cells, which is an important component in the treatment of viral infections. Other hemp compounds with different chemical structures have also shown antiviral activity.  

Several preclinical studies have examined the possible role of CBD as an antiviral agent. One study showed a direct antiviral effect against hepatitis C. Another showed an indirect viral effect of cannabidiol against herpesvirus associated with Kaposi’s sarcoma. CBD treatment also prevented the conversion of cells to cancerous lesions. Another study showed that cannabidiol mitigates the effects of neuroinflammation caused by the Teyler mouse encephalomyelitis virus.

Coronavirus may create clinical opportunity

Studies show that cannabidiol is a reasonable candidate to study in preclinical models of coronavirus. We are very far from the level of evidence needed to consider the use of cannabinoids as pharmacotherapy for viral diseases, but the continued high interest in cannabinoids as drugs provides an important opportunity for clinicians. Therefore, practitioners should be interested in the experience of our patients with cannabinoids and at least the tangible benefits of their use or their hopes for how cannabinoids can help in the health condition they are trying to manage.

Attached to this opportunity is the obligation to inform our patients on the basis of evidence about the future of cannabinoids and the limitations of our current knowledge. The Internet is a leading source of health-related information and many tend to exaggerate the current state of cannabinoid science or completely distort it. 

Commentary by the Ukrainian Technical Hemp Association

“Cannabis and Cannabinoid Research” is a journal dedicated to the scientific, medical and psychosocial research of clinical experiments with hemp, cannabinoids and the endocannabinoid system.

States and companies continue to profit from the sale of cannabis, but only a few fund the necessary research into the therapeutic properties of the plant. Unfortunately, the use of hemp for medical and scientific purposes in Ukraine is not currently regulated, therefore, the results of the experiments carried out by national scientists in the economically developed countries of the world below in our country can not be confirmed or disproved, so far it is only necessary to describe the data obtained by our foreign colleagues confirming the effectiveness of the use of cannabinoids for the treatment of severe, including chronic, diseases.

Secondary plant metabolites (organic substances synthesized by the body, but not involved in growth, development or reproduction) have significant antibacterial, antimicrobial, antiviral properties. These include aromatic compounds, for example terpenes and terpenoids. There is a lot of scientific data on terpenes and terpenoids with a powerful therapeutic effect. In addition, in the varieties of therapeutic hemp bred and registered in Ukraine, a number of elements unknown to modern science with huge therapeutic properties were found. We take into account the “ensemble effect”, already known to science, of a gamut of therapeutically active elements with significant antiviral properties and we make food or biologically active additives based on the leaves and inflorescences of hemp plants that effectively work as a powerful tool that can fight against viral diseases, including including COVID 19. 

Doctors have an excellent rule: “The best treatment is prevention.” Already there is an experience of using leaves and inflorescences of therapeutic hemp varieties of therapeutic orientation as a cheap and effective prophylactic, including those used for the prevention of coronavirus. In addition, the results of studies on volunteers suggest that in the case of severe diseases associated with COVID 19, biologically active additives made on the basis of the therapeutic properties of technical hemp, reinforced with an organomineral complex based on humic substances, extremely effectively cure patients, preventing negative consequences of the course of diseases for the human body.

Источник: 
Обучение в рамках "Конопляного Университета"
15.09.2020

Объявления
Все объявления »
 
 

facebook

telegram

twitter